definiens: means all revenue generated by, and all considera tion received by, GRAIL or any of its Operational Affiliates from or in connection with any activities in or directed to the field of Oncology, or otherwise arising from or attributable to the field of Oncology, other than revenue gener ated, or consideration received, from or in connection with the Sale of Oncology Products and Oncology Services . For example, and without limitation, Other Oncology Rev enue includes revenues generated from the licensing ( or granting of similar rights ) under GRAIL Intellectua l Property Rights excluding GRAIL In - Licenses in th e field of Oncology . If GRAIL or its Operational Affiliate receives non- cash consideration ( including shares of equity or in- kind contribution of goods or services ), or consideration in a transaction that is not at arm ’s length ( including any transfer of Technology or Intellectu al Property Rights to an Affiliate ), from any activ ities in or directed to the field of Oncology, or otherwise ari sing from or attributable to the field of Oncology ( other than the Sale of Oncology Products and Oncology Services ) such consideration will be included in Other Onco logy Revenue based on the fair market value of such cons ideration, as determined by the good faith negotiat ion of the Parties . Any Dispute as to the fair market value of such consideration will be resolved pursuant to th e expedited Dispute resolution proceedings of Section 14.2(c ) . Notwithstanding the foregoing, Other Oncology Reven ue does not include consideration received as reimburs ement for costs incurred pursuant to a collaboratio n with a Third Party ( including overhead and personnel costs ), reimbursement for GRAIL ’s purchase of equipment or supplies, payments received in the form of grants f or research from governmental entities or non- prof it organizations, or Intellectual Property Rights rece ived as part of a collaboration ( though Royalty may be due resulting from the exploitation of such Intellectua l Property Rights, as otherwise required by this Ag reement ), or payments received for purchase of GRAIL shares at f air market value ( provided that any premium would n ot be excluded )